New collaboration enhances Dario's
comprehensive GLP-1 offering with virtual physician management to
meet growing demand from employers covering weight-loss
medications, opening new revenue streams in
direct-to-consumer and pharma channels
NEW
YORK, Jan. 14, 2025 /PRNewswire/ -- January 14, 2025 -- DarioHealth Corp.
(Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global
digital health market, today announced a collaboration with
MediOrbis, a multi-specialty digital health provider, to add
prescribing capabilities to Dario's GLP-1 behavior change solution
for a comprehensive medical weight loss program. This strategic
addition creates a fully integrated solution for employers covering
weight-loss medications and supports direct-to-consumer offerings,
expanding Dario's addressable market in one of the fastest-growing
segments of digital health.
Employer coverage of GLP-1 medications for weight loss continues
to grow, with a recent survey from Mercer showing 44% of large
employers now covering obesity drugs.[1] As more employers cover
obesity medications, the rising costs of these drugs highlight the
need for strategic plan designs that ensure judicious use of
medications in close collaboration with behavior change programs to
drive sustainable clinical outcomes while maximizing
return-on-investment (ROI). Dario's aim is to ensure the drug is
prescribed to the right people and to facilitate successful
onboarding and offboarding processes. The Company leverages its
unique expertise in behavior change to guide users through a
healthy and effective GLP-1 journey, resulting in real, sustainable
weight loss through lifelong healthy lifestyle modification. This
new collaboration enhances Dario's comprehensive GLP-1
solution by adding a key physician oversight including prescribing
capability, positioning the Company to potentially drive recurring
revenue and expand its addressable market in response to growing
employer demand for holistic, cost-effective weight management
programs.
Dario works with employers to support a wide range of GLP-1
benefits strategies by delivering the GLP-1 behavior change
solution as required under plan design to help employees
successfully lose weight and improve measurable results before,
during and after the use of a GLP-1 medication. The addition of
MediOrbis prescribing capabilities extends Dario's ability to
optimize outcomes and ROI for employers by layering seamless access
to care across the behavior change journey for people who are most
likely to benefit from the addition of a GLP-1 medication.
"The GLP-1 market is rapidly expanding, but employers need more
than access to medications—they need a solution that drives
long-term health improvements and cost savings," said Steven Nelson, Chief Commercial Officer at
Dario. "Our new collaboration with MediOrbis completes our
end-to-end GLP-1 solution, enabling us to meet this demand by
combining virtual prescribing with proven behavior change programs.
We believe that this strategic move positions Dario to capture more
opportunities in the employer and direct-to-consumer markets while
delivering actionable insights to our pharma partners, opening new
pathways for recurring revenue."
Dr. Omar Manejwala, Chief Medical
Officer at Dario commented: "Achieving sustainable weight loss with
GLP-1 medications requires more than just a prescription—it demands
continuous, personalized support to maintain results. We believe
that our collaboration with MediOrbis strengthens our ability to
provide seamless, high-quality virtual care that complements our
behavior change programs, ensuring members achieve meaningful
health outcomes while employers see long-term value from their
investment."
Dr. Jonathan Wiesen, Co – Founder
and Chief Medical Officer of MediOrbis commented: "We are excited
to collaborate with Dario to leverage digital care to address and
manage obesity and other specialty and chronic illnesses, which are
the most prevalent and resource-consumptive health
conditions. This collaboration allows us to continue to seek
to innovate and develop meaningful clinical programs that impact
the health, productivity and well-being of employees
worldwide."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Dario's platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Dario's user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it
discusses the future market growth of GLP-1 medications for
weight loss, the benefits to employers and patients resulting from
the collaboration between the Company and MediOrbis, and the
potential of the collaboration to position the Company to drive
recurring revenue and expand its addressable market. Without
limiting the generality of the foregoing, words such as "plan,"
"project," "potential," "seek," "may," "will," "expect," "believe,"
"anticipate," "intend," "could," "estimate" or "continue" are
intended to identify forward-looking statements. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
1. Employers enhanced health benefits in 2024,
adding coverage for weight-loss medications and IVF despite growing
health cost.
Logo:
https://mma.prnewswire.com/media/1920436/3708722/DarioHealth_Logo.jpg
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat
Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
View original
content:https://www.prnewswire.com/news-releases/dariohealth-expands-glp-1-solution-with-prescribing-capabilities-through-collaboration-with-mediorbis-targeting-employers-and-direct-to-consumer-markets-302350296.html
SOURCE DarioHealth Corp.